A Disease You Catch Slowly and Carry Forever: India's Race to End Filariasis by 2027
West Bengal's mass drug administration drive resumes a campaign that lost four years to COVID — against a target three years ahead of the global one
What happened
Most disease questions reward describing a pathogen. This one rewards understanding a strategy, because filariasis is the clearest case in Indian public health of a disease that individual treatment cannot defeat. The drug is given to healthy people, in an area rather than to patients, on a schedule that must not break — which makes MDA a governance problem far more than a clinical one, and makes the four-year COVID interruption the single most examinable fact here.
Why Filariasis Needs Mass, Not Patient, Treatment
The Logic of the Strategy
| Dominant parasite | W. bancrofti (~90%) |
| Vector in India | Culex quinquefasciatus |
| India's target | End-2027 |
| WHO / SDG target | 2030 |
| MDA suspended → resumed | Mar 2020 → Feb 2024 |
Source: Ministry of Health and Family Welfare; WHO Global Programme to Eliminate Lymphatic Filariasis
Lymphatic filariasis is a parasitic infection caused by filarial nematodes of the family Filarioidea: Wuchereria bancrofti, which accounts for roughly 90 per cent of cases globally and is the dominant species in India, along with Brugia malayi and Brugia timori.
●It is transmitted by mosquitoes — in India chiefly Culex quinquefasciatus, which breeds in polluted, stagnant water, tying transmission directly to sanitation and drainage.
●Adult worms lodge in the lymphatic vessels; microfilariae circulate in the blood and are picked up by biting mosquitoes.
●Infection requires repeated infective bites over months or years, and most infections remain asymptomatic while still transmissible.
●Chronic manifestations — lymphoedema, elephantiasis and hydrocele — typically appear years later and are largely irreversible, which is why the programme runs two arms: Mass Drug Administration (MDA) to interrupt transmission, and Morbidity Management and Disability Prevention (MMDP) for those already affected.
●MDA delivers an annual preventive dose to the entire at-risk population, using diethylcarbamazine with albendazole, or the triple-drug IDA regimen adding ivermectin.
●Success is verified through a Transmission Assessment Survey, which determines when MDA may stop.
●The WHO's Global Programme to Eliminate Lymphatic Filariasis targets 2030; India targets the end of 2027.
The drug is given to healthy people, by area rather than by diagnosis, and the schedule must not break — a strategy whose weak point is administrative continuity, which is exactly what the four-year COVID suspension destroyed.
◎ In Simple Words
Lymphatic filariasis is caused by tiny worms spread by mosquito bites. You do not get it from one bite — it takes many bites over months or years. Most people who carry the worms feel nothing at all, so they never go to a doctor, but they can still pass it on. Years later, some people develop badly swollen legs or arms, which is why it is called elephantiasis. Because carriers feel fine, doctors cannot wait for patients to come. Instead, everyone in an affected area takes a preventive tablet once a year, for several years in a row, until the worms have nowhere left to spread.
Factual Pointers
Practice · 2 questions
With reference to lymphatic filariasis, consider the following statements:
1. It is caused by a protozoan parasite transmitted by the Anopheles mosquito.
2. The majority of infections remain asymptomatic while still being transmissible.
3. Its control strategy involves administering preventive medication to an entire at-risk population rather than only to diagnosed patients.
Which of the statements given above are correct?
Consider the following statements about India's lymphatic filariasis elimination programme:
1. India's target date for elimination as a public health problem is earlier than the global WHO target.
2. A Transmission Assessment Survey is used to determine when Mass Drug Administration can be stopped in an area.
Which of the statements given above is/are correct?
Mains Practice Questions
"For diseases whose carriers are asymptomatic, public health must treat geography rather than patients." Critically examine this proposition with reference to India's lymphatic filariasis elimination programme. (250 words, GS2)
The COVID-19 pandemic imposed its heaviest long-term costs on routine preventive health programmes rather than on emergency care. Discuss with examples. (250 words, GS2)
Elimination targets measure transmission interruption, not the welfare of those already disabled. Examine this gap with reference to neglected tropical diseases in India. (150 words, GS2)
Frequently Asked
· People also askWhat causes lymphatic filariasis?
It is caused by filarial nematodes (roundworms) of the family Filarioidea — Wuchereria bancrofti, which accounts for about 90 per cent of cases globally and dominates in India, along with Brugia malayi and Brugia timori. Adult worms lodge in the lymphatic vessels.
Prelims · GS3It is a parasitic worm infection, not a protozoal or bacterial one — a common confusion, since malaria in the same regions is protozoal. The WHO classifies it as a neglected tropical disease.
SOURCE World Health Organization
Which mosquito transmits filariasis in India?
Chiefly Culex quinquefasciatus, which breeds in polluted, stagnant water such as open drains and waterlogged sites. This distinguishes it from the Anopheles vector of malaria, which prefers relatively clean water, and ties filariasis burden directly to drainage and sanitation.
Prelims · GS3Because the vector thrives on sanitation failure, an area cleared by drug administration remains reinvadable unless drainage and wastewater management improve — which is why LF elimination is inseparable from urban sanitation policy.
SOURCE National Center for Vector Borne Diseases Control
What is Mass Drug Administration and why is it used?
MDA delivers an annual preventive dose to an entire at-risk population regardless of infection status, using diethylcarbamazine with albendazole or the triple-drug IDA regimen adding ivermectin. It is used because most carriers are asymptomatic yet infectious, so treating only diagnosed patients cannot interrupt transmission.
GS2 · HealthIt must be repeated for several consecutive years until a Transmission Assessment Survey confirms prevalence has fallen below the threshold at which mosquitoes can sustain transmission.
SOURCE Ministry of Health and Family Welfare; WHO
What is India's target date for eliminating filariasis?
India aims to eliminate lymphatic filariasis as a public health problem by the end of 2027 — three years ahead of the WHO Global Programme to Eliminate Lymphatic Filariasis and the Sustainable Development Goal target of 2030.
Prelims · GS2Elimination is certified district by district through Transmission Assessment Surveys, so a few persistently under-covered pockets can hold back validation for an entire state despite good national averages.
SOURCE Ministry of Health and Family Welfare
How did COVID-19 affect the filariasis programme?
Mass drug administration and related activities were suspended in March 2020 and resumed only in February 2024 — a four-year interruption. Because MDA works by holding prevalence below a transmission-sustaining threshold, a break allows rebound, so the campaign resumed from behind where it stopped.
GS2 · GovernanceA 2026 study in Scientific Reports documented high bancroftian filariasis prevalence and comorbidities in eastern coalfield districts of West Bengal following that disruption — evidence of how quickly gains erode.
SOURCE Scientific Reports (Nature), 2026
Can elephantiasis be cured once it develops?
Largely no. Chronic manifestations — lymphoedema, elephantiasis and hydrocele — are mostly irreversible, which is why the programme runs a second arm, Morbidity Management and Disability Prevention (MMDP), providing lifelong limb care, hygiene training and surgery for hydrocele.
GS2 · Social JusticeThis means even complete success on transmission by 2027 leaves a large existing cohort needing lifelong support against severe social stigma — a group that transmission-focused elimination metrics systematically underserve.
SOURCE World Health Organization
Why do people not take the MDA tablets?
Because the request is behaviourally difficult: healthy people are asked to take annual tablets for a disease they do not have, with mild transient side effects that are more noticeable than an invisible benefit. Systematic under-consumption follows — tablets are accepted but not swallowed.
GS2 · GovernanceEffective programmes therefore rely on supervised consumption, trusted frontline workers such as ASHAs, and visible community endorsement. The failure mode is social rather than pharmacological, which also obliges honest communication about side effects.
SOURCE Ministry of Health and Family Welfare